We are live on ! Find out more
KAM

Kazazian Asset Management Portfolio holdings

AUM $91.5M
1-Year Est. Return 35.36%
This Fund
S&P 500
This Quarter Est. Return
+4.85%
1 Year Est. Return
+35.36%
3 Year Est. Return
–
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$97.9M
AUM Growth
+$16.2M
Cap. Flow
+$13.7M
Cap. Flow %
14.05%
Top 10 Hldgs %
51.86%
Holding
86
New
16
Increased
49
Reduced
9
Closed
4

Top Buys

Rank Stock Value
1
CS
Credit Suisse Group
CS
+$1.79M
2
NS
NuStar Energy L.P.
NS
+$1.64M
3
BCS icon
Barclays
BCS
+$1.41M
4
MLPA icon
Global X MLP ETF
MLPA
+$988K
5
EXPE icon
Expedia Group
EXPE
+$960K

Top Sells

Rank Stock Value
1
BIIB icon
Biogen
BIIB
+$408K
2
IMGN
Immunogen Inc
IMGN
+$357K
3
CMG icon
Chipotle Mexican Grill
CMG
+$273K
4
SRPT icon
Sarepta Therapeutics
SRPT
+$265K
5
PPLI
People Inc
PPLI
+$249K

Sector Composition

Rank Sector Weight
1 Healthcare 24.97%
2 Consumer Discretionary 11.02%
3 Financials 10.96%
4 Communication Services 6.9%
5 Energy 5.68%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
CLF icon
76
Cleveland-Cliffs
CLF
$6.99B
$95K 0.1%
13,161
+1,047
+9% +$6.96K
OMED
77
DELISTED
OncoMed Pharmaceuticals, Inc.
OMED
$80K 0.08%
+19,512
New +$84.9K
RCKT icon
78
Rocket Pharmaceuticals
RCKT
$394M
$68K 0.07%
+6,504
New +$64.5K
NERV icon
79
Minerva Neurosciences
NERV
$199M
$63K 0.06%
+1,301
New +$64.5K
MTL.PR
80
DELISTED
Mechel PAO American Depositary Shares (each representing one-half of a Preferred Share)
MTL.PR
$47K 0.05%
44,298
– –
EQS icon
81
Equus Total Return
EQS
$16.8M
$46K 0.05%
19,073
– –
GMO
82
DELISTED
General Moly, Inc.
GMO
$7K 0.01%
20,895
– –
GREK
83
Global X MSCI Greece ETF
GREK
$316M
– –
-4,800
Closed -$136K
PCRX icon
84
Pacira BioSciences
PCRX
$997M
– –
-5,247
Closed -$197K
SRPT icon
85
Sarepta Therapeutics
SRPT
$1.77B
– –
-5,832
Closed -$265K
IMGN
86
DELISTED
Immunogen Inc
IMGN
– –
-46,644
Closed -$357K
1 2 3
4

Similar funds

MRP
Measured Risk Portfolios San Diego, California $91.4M AUM 0.88% 1-Year Est. Return
ITG
Index Technologies Group New York $91.8M AUM
MA
Marquette Associates Chicago, Illinois $91.9M AUM 13.47% 1-Year Est. Return
AW
Aspirean Wealth Mill Valley, California $92.1M AUM
SPCM
Spruce Point Capital Management New York $90.9M AUM
ML
MLP3 LLC Linwood, New Jersey $90.7M AUM
ICM
Incision Capital Management San Francisco, California $90.6M AUM
ACMC
Anchor Capital Management Company Raleigh, North Carolina $92.7M AUM 19.36% 1-Year Est. Return

Kazazian Asset Management's Q4 2017 Portfolio in Review

As of Q4 2017, Kazazian Asset Management held 86 positions worth $97.9M, up 20% from $81.7M the previous quarter. Its ten largest holdings account for 52% of the portfolio.

Kazazian Asset Management deployed $13.7M of net new capital in Q4 2017, opening 16 new positions and adding to 49 existing holdings. Its largest new stake was Credit Suisse Group: 108,000 shares worth $1.93M.

By sector, the portfolio is most concentrated in Healthcare at 25% of assets, up from 24% a quarter earlier, followed by Consumer Discretionary and Financials.

On the sell side, the largest reduction was Biogen, an estimated $408K trimmed.

  • Kazazian Asset Management's largest Q4 2017 buy was Credit Suisse Group: 108,000 shares worth $1.93M.
  • Kazazian Asset Management added most to State Street SPDR S&P 500 ETF Trust in Q4 2017, an estimated $846K increase.
  • Kazazian Asset Management's biggest Q4 2017 reduction was Biogen, cutting an estimated $408K.
  • Kazazian Asset Management fully exited Immunogen Inc in Q4 2017, selling an estimated $357K.
  • Kazazian Asset Management's ten largest holdings make up 52% of its $97.9M portfolio in Q4 2017.
  • Kazazian Asset Management opened 16 new positions and closed 4 in Q4 2017.
  • Kazazian Asset Management's portfolio value rose 20% quarter-over-quarter to $97.9M.

Based on Kazazian Asset Management's 13F filing for Q4 2017, filed 15 Feb 2018.